We performed a pragmatic clinical trial with an off-on study design alternating weekly between intervention (GI PROMIS) and control arms at one Veterans Affairs and three university-affi liated specialty clinics. Adults with GI symptoms were eligible. Intervention patients completed GI PROMIS symptom questionnaires on an e-portal 1 week before their visit; PROs were available for review by patients and their providers before and during the clinic visit. Usual care patients were managed according to customary practices. Our primary outcome was patient satisfaction as determined by the Consumer Assessment of Healthcare Providers and Systems questionnaire. Secondary outcomes included provider interpersonal skills (Doctors' Interpersonal Skills Questionnaire (DISQ)) and shared decision-making (9-item Shared Decision Making Questionnaire (SDM-Q-9)). 
INTRODUCTION
Patients oft en seek care because they experience symptoms that negatively impact health-related quality of life. Healthcare providers must elicit, measure, and interpret patient symptoms as part of their clinical evaluation. To assist with this goal, researchers have developed and validated a wide range of patient-reported outcomes (PROs) across diseases, with a focus on chronic illnesses ( 1-3 ). Th ese PROs, which measure any aspect of a patient's biopsychosocial health that comes directly from the patient, may help direct care and improve outcomes. When PROs are collected systematically, effi ciently, and in the right place at the right time, they may enhance the patient-provider relationship at the center of chronic disease care, improve communication, and help make shared decisions (4) (5) (6) .
However, despite the promise of using PROs to guide patient care, there are important challenges to applying PROs in routine practice (7) (8) (9) (10) (11) (12) . For example, it can be time consuming to collect PROs from patients and securely transmit the data into the electronic health record (EHR), making it untenable for use in busy practices. Th ere are also many PROs to choose from, with a lack of measurement standards across questionnaires. Furthermore, clinicians note that it can be diffi cult to understand and act upon PRO scores. When coupled with limited evidence from previous research that administering PROs truly impacts patient outcomes ( 2 ), these challenges limit widespread use of PROs in clinical practice; most providers instead opt for informal measurement of symptoms and function.
In this context, the National Institutes of Health (NIH) created the Patient Reported Outcomes Measurement Information System (PROMIS) in 2004 with the goal of developing, validating, and disseminating a toolbox of publicly available PROs that cover the breadth and depth of the human illness experience while overcoming technical challenges of applying PROs in practice (http: // www. nihpromis.org ) ( 13 ) . Using modern psychometric techniques, such as item response theory and computerized adaptive testing ( 14, 15 ) , PROMIS off ers state-of-the-art psychometrics, establishes common-language benchmarks for symptoms across conditions, and identifi es clinical thresholds for action and meaningful clinical improvement or decline. PROMIS questionnaires are administered electronically and effi ciently, allowing implementation in busy clinical settings. Because of the extraordinary burden of illness from digestive diseases, the PROMIS consortium added a gastrointestinal (GI) item bank, which our group developed ( 16 ) . Using the NIH PROMIS framework, we constructed and validated eight GI PROMIS symptom scales using data from over 2,000 subjects (16) (17) (18) .
However, despite over a decade of NIH PROMIS development, it remains unclear whether implementing GI PROMIS, let alone any PROMIS measures, can improve patient outcomes vs. usual care. In this study, we conducted an NIH-supported multicentercontrolled trial of PROMIS vs. usual care in clinical practice. Speci fi cally, we used GI PROMIS measures in diverse patients with active GI symptoms, collected the results via a patient-provider e-portal, and presented the data at the point of care. We hypothesized that compared with usual care, use of GI PROMIS would enhance the patient-provider interaction, leading to improved patient satisfaction and higher patient assessment of provider interpersonal skills and shared decision-making.
METHODS

Study overview
We performed a pragmatic, multicenter clinical trial comparing use of validated GI PROMIS questionnaires ( 16 ) vs. usual care in diverse patients with active GI symptoms, including those with abdominal pain, bowel incontinence, bloating/gas, constipation, diarrhea, dysphagia, heartburn/refl ux, and nausea/vomiting. We administered the GI PROMIS questionnaires through a secure, online, patient-provider e-portal (see Appendix Figure 1 for sample screenshots). Th e portal collected the PRO data and converted responses into a symptom "heat map" ( Figure 1 ) that visually compared each patient's symptoms against the general US population ( 16, 18 ) . Both patients and providers could view this heat map on the portal before and during the clinic visit.
To enhance clinical applicability of GI PROMIS, the e-portal autocomposed a complete GI history of present illness (HPI) report triggered off the PROMIS symptoms. Patients were guided through a set of questions measuring the timing, severity, frequency, location, quality, and character of each reported GI PROMIS symptom, along with relevant comorbidities, family history, and alarm features ( 19, 20 ) . Once the questions were completed, the information was transformed into a full narrative GI HPI that accompanied the PROMIS heat map ( Figure 1 ). In a previous head-to-head trial comparing GI PROMIS-directed computerized HPIs vs. physician HPIs, we found that the computerized HPIs were rated by blinded reviewers to be of higher quality and more thorough, complete, succinct, and relevant ( 19 ) . However, HPI: Mr. Smith is a 34-year-old male who reports a history of Celiac disease and now presents with abdominal pain. The pain first started 8 months ago, and typically lasts for 2 hours at a time. Over the past week, the pain occurred once a day. He describes the pain as "burning" and "gnawing", says it is located in the epigastrium, and reports the pain has been "quite severe" and "quite a bit bothersome" in the past week. It does not radiate. It is associated with eating food. It typically occurs around 10-30 minutes after starting to eat. It usually comes on suddenly. It is not associated with bowel movements. The pain is somewhat relieved by reducing stress. The pain does not awaken him from sleep. He does not report early satiety. He does not report diabetes, gallstones, GERD, pancreatitis, or peptic ulcer. He does not take aspirin or NSAIDs.
He also reports diarrhea and bowel incontinence. The patient does not report dysphagia, heartburn, bloating, constipation, nausea, or vomiting.
He does not report blood in his bowel movements, black stools, vomiting blood, unintended weight loss, diminished appetite, or fevers. He has no history of abdominal surgeries. There is a family history of colorectal cancer. the previous trial did not measure the impact of the PROMIS on patient outcomes. By tying GI PROMIS scores to a focused HPI, using specifi c GI symptoms with benchmarked interpretation, and directly presenting the results to the provider at the point of care, we attempted to optimize the impact of using PROMIS. In this manner, the current study sought to overcome traditional critiques of using PROs in clinical practice: i.e., technical diffi culties of transmitting to the EHR, interpretability, data visualization issues, and clinical actionability.
Study design, patients, and setting
We used a pragmatic, off -on study design alternating weekly between the PROMIS intervention and control arms. Patients who visited the following clinics were eligible for the study: (i) Cedars-Sinai Medical Center general GI clinic; (ii) West Los Angeles Veterans Aff airs (WLAVA) Medical Center general GI clinic; (iii) University of Michigan functional GI and motility clinic; and (iv) University of Michigan scleroderma clinic (selected because scleroderma patients have a high prevalence of GI symptoms). Th e Cedars-Sinai and WLAVA GI clinics are academic teaching practices staff ed by GI attending physicians; the initial evaluation in these clinics were primarily conducted by GI specialty fellows, internal medicine residents, or physician assistants. Conversely, attending physicians primarily staff ed the GI and scleroderma clinics at the University of Michigan.
We enrolled patients, aged ≥18 years, who were scheduled for an initial visit or had not been seen in the clinic within the past 8 months. Patients were also required to read and write English and possess basic point-and-click computing skills.
During the control weeks, patients were treated according to all customary practices. In the intervention weeks, eligible patients were mailed a letter 1 week before their appointment inviting them to log on to the e-portal to complete GI PROMIS. Eligible intervention patients who did not complete PROMIS before their visit were also approached during the day of their appointment by research staff and again invited to access the e-portal on a clinic computer before seeing their physician. Clinic providers were informed to access the e-portal and view the GI PROMIS symptom heat map for patients who completed PROMIS. In keeping with our pragmatic approach to the study, providers were not mandated to use the PROMIS data or PROMIS-directed HPI. Rather, providers were allowed to make individual decisions on how to use the PROMIS data report, if at all.
Within 24 h of completing the clinic visit, patients were sent the postvisit questionnaires to measure their satisfaction with the visit as well as their assessment of their providers' interpersonal skills and shared decision-making. Th is study was approved by the Institutional Review Boards (IRBs) at all sites (Cedars-Sinai IRB Pro00041476; University of Michigan IRB HUM00063094; WLAVA IRB PCC no. 2013-111563).
Primary and secondary outcomes
Th e primary outcome was patient satisfaction as measured by the Consumer Assessment of Healthcare Providers and Systems Clinician and Group Survey 2.0 (CG-CAHPS) ( 21 ) . Because the CG-CAHPS is a global assessment of patients' satisfaction with their medical care over the past year, we used selected items that were applicable for assessing patient satisfaction aft er a single visit. Patients were reminded to answer the questions thinking about their most recent visit to the GI or scleroderma clinic. Th e answer options for most selected CG-CAHPS items were "Yes, defi nitely, " "Yes, somewhat, " and "No. " We used a "top-box" approach, which is commonly used when reporting CG-CAHPS data ( 22 ) ; a positive response included only "Yes, defi nitely, " while negative responses included "Yes, somewhat" or "No. "
Our secondary outcomes were patient assessments of provider interpersonal skills and shared decision-making. Patients completed the Doctors' Interpersonal Skills Questionnaire (DISQ) to assess their provider's interpersonal skills ( 23 ) . Th e DISQ comprised 12 items, each scored on a 5-point scale, where 1="Poor" and 5="Excellent. " We converted each item to a 100-point scale and averaged the scores for the 12 items to calculate an overall interpersonal skills score.
We used the 9-item Shared Decision Making Questionnaire (SDM-Q-9) to assess patient shared decision-making ( 24 ) . Th e SDM-Q-9 contained nine items, each scored on a 6-point scale, where 1="Completely Disagree" and 6="Completely Agree. " Similar to the DISQ, we converted each item to a 100-point scale and averaged the nine scores to calculate an overall shared decisionmaking score. Again, for both DISQ and SDM-Q-9, patients were informed to answer the questions thinking about their most recent GI or scleroderma clinic visit.
Covariates
We also collected information on potentially confounding patientand provider-level variables. Patient-level factors included age, gender, and race/ethnicity. We also collected provider-level factors, including site of care and provider level of training.
Sample size calculation
Our primary objective was to measure diff erences in CG-CAHPS provider rating scores between groups. Although CG-CAHPS is widely used and accepted as a measure of patient satisfaction with outpatient visits, we are unaware of data measuring the minimally clinically important diff erence on the scale. Th erefore, the sample size was calculated to achieve an eff ect size of 0.5 (a half standard deviation diff erence) in mean CG-CAHPS provider rating scores between groups-an eff ect size that is moderate and generally correlates with the minimally clinically important diff erence ( 25, 26 ) . Assuming a two-tailed 5% signifi cance level with a power of 80%, the minimum sample size needed to show an eff ect size of 0.5 was 64 patients per group.
Statistical and sensitivity analyses
Statistical analyses were performed using Stata 13.1 (StataCorp LP, College Station, TX). A two-tailed P value <0.05 was considered signifi cant. Our primary analyses were performed from the intention-to-treat perspective. For intervention patients who completed GI PROMIS, but did not return the postvisit out-
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come surveys, we assumed their outcomes (CG-CAHPS provider rating, DISQ, and SDM-Q-9) were no diff erent than controls. Specifi cally, the missing outcome data for this group was imputed to the corresponding mean value calculated from controls for each item. Because this assumption biases towards the null, we also performed a sensitivity analysis using a per-protocol approach where we excluded patients without follow-up data.
For bivariate analyses, we used the two-sample t -test and χ 2 test to compare means and proportions, respectively, between groups. We performed a multivariable logistic regression model to identify patient characteristics that were independent predictors of completing PROMIS before the clinic visit.
We used linear regression to generate an adjusted P -value and to evaluate diff erences in CG-CAHPS provider ratings between groups while adjusting for potential confounding patient-and provider-level factors. We used similar approaches when comparing the remaining CG-CAHPS items (Firth logistic regression) and the DISQ and SDM-Q-9 items (linear regression). Figure 2 shows patient fl ow through the clinical trial. Overall, 502 patients were assigned to the control arm and 3 (0.6%) had missing demographic data. Of the 499 with complete covariate data, 154 (30.9%) completed the postvisit outcome questionnaires. Signifi cant diff erences were seen between completers and noncompleters with respect to age, gender, and site of care; no diff erence in race/ethnicity was noted between groups ( Appendix Table 1 ). Table 1 presents the demographics of patients in the control arm.
RESULTS
Study population
For the intervention group, 594 (0% missing demographic data) were invited to complete GI PROMIS before their clinic visit. Among those invited, 221 (37.2%) accessed the e-portal and completed the questionnaires. A majority of the patients who completed PROMIS attended their clinic appointment (217/221; 98.2%). Of the 217 individuals who completed PROMIS and attended their clinic visit, 112 (51.6%) completed the postvisit outcome assessments. Signifi cant diff erences were seen in age and site of care between those who did and did not return the surveys; no diff erences were seen in gender and race/ethnicity between groups ( Appendix Table 2 ). In Table 1 , we list the demographics of those in the GI PROMIS arm. Table 2 shows the results from the multivariable regression on completion of GI PROMIS before the clinic visit. Age and gender were not independent predictors of completing PROMIS. African Americans were less likely to access the e-portal vs. whites (odds ratio 0.44; 95% confi dence interval 0.26, 0.74); no diff erences were seen between whites and the remaining racial/ethnic groups (Latino, Asian, Other/Unknown). Conversely, patients seen at the University of Michigan GI clinic were more likely to complete PROMIS vs. patients at the WLAVA GI clinic (odds ratio 7.96; 95% confi dence interval 4.19, 15.1).
Predictors of completing GI PROMIS
Primary and secondary outcomes
Intention-to-treat analyses . Table 3 presents the CG-CAHPS provider rating scores for the GI PROMIS and control arms in the intention-to-treat analysis. Aft er adjusting for confounders, we found no diff erence in provider rating between groups. Tables 4 and 5 list diff erences in provider interpersonal skills and shared decision-making, respectively. We found no diff erence in DISQ scores between the PROMIS and control arms. Both groups also had similar shared decision-making scores as by the SDM-Q-9.
Per-protocol analyses . Because the intention-to-treat analysis biases results towards the null, we also performed a per-protocol analysis. Here, there were 154 individuals in the control group and GI PROMIS scores may be insuffi cient to meaningfully improve patients' interaction with the healthcare system. Th ese results are also in line with a systematic review that found inconsistent benefi ts of applying PROs in clinical practice ( 2 ).
Th ere are several possible explanations for our negative results. First, despite the wide use of CG-CAHPS for assessing patient satisfaction, the minimally clinically important diff erence for the scale is unknown; it is possible that the study was underpowered to detect a signifi cant and meaningful diff erence between groups. Because of this issue, we calculated the sample size to achieve a moderate eff ect size of 0.5, which prior research found generally correlates with the minimally clinically important diff erence ( 25, 26 ) . Second, patients reported high levels of satisfaction in both arms of this trial. Th is result may have led to a "ceiling eff ect"; it is possible that PROMIS on its own may not off er incremental improvements among patients who are already satisfi ed with their provider. Th ird, only 30.9% and 51.6% of patients in the control and intervention arms, respectively, completed the postvisit outcome questionnaires; we cannot know if outcomes would be diff erent in survey non-responders. Fourth, we focused on a proximal outcome of patient satisfaction aft er a single clinic visit; it is possible that longitudinal use of GI PROMIS (i.e., to track GI symptom improvement and response to therapies) may have led to improved patient satisfaction over time. Last, in keeping with the study's pragmatic approach, we did not mandate or assess the use of PROMIS scores 112 in the GI PROMIS arm. Th ere were no diff erences between groups with respect to age, gender, race/ethnicity, site of care, or provider level of training (all P >0.05).
Th e results were similar: there was no diff erence in CG-CAHPS provider ratings between groups (control 8.93±1.65 vs. GI PROMIS 8.84±1.64; adjusted P =0.76). Both groups had similar patient satisfaction scores for the remaining CG-CAHPS items ( Table 3 ) . Patient assessment of provider interpersonal skills ( Appendix Table 3 ) and shared decision-making ( Appendix Table 4 ) were also similar between both arms.
DISCUSSION
To our knowledge, this is the fi rst controlled trial evaluating the impact of PROMIS on patient outcomes in clinical practice. Despite theoretical benefi ts of measuring GI PROs to drive clinical decision-making, we found no diff erences in patient satisfaction or assessment of provider interpersonal skills and shared decision-making between those in the NIH GI PROMIS and control arms. Th ese results suggest that simply measuring 
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or PROMIS-directed HPI reports by providers. It is possible that some clinicians did not use the report and managed the patient according to their customary practices. While we could have tested the effi cacy of GI PROMIS in a tightly controlled setting by mandating that all providers use PROMIS and incorporate it into their patient assessment, we instead sought to test the eff ectiveness of PROMIS in a setting that more resembles the "real world. " Our study also has limitations with respect to external generalizability. We only evaluated patients with GI symptoms, thus we cannot know whether using other PROMIS questionnaires, such as those for fatigue, physical function, or pain, among many others, would also fail to show a diff erence vs. usual care. Moreover, our trial was conducted solely in clinics affi liated with academic universities. It is possible that outcomes may be diff erent when GI PROMIS is used in non-university-based clinics, but that must be formally tested and it is the subject of our future research.
Despite these limitations, we found no diff erences between groups. Even with post hoc analyses searching for diff erences on an item-by-item basis, the groups were equivalent. Th is is consistent with existing literature that administering PROs, although conceptually appealing, oft en fails to meaningfully improve patient outcomes vs. usual care ( 2 ) . Notably, we attempted to overcome this problem by tying GI PROMIS to a full narrative GI HPI, off ering the reports on a computer interface viewable in the clinic, making the results available both before and during the clinic to patients and their providers, and visualizing the scores with a heat map that displays percentile scores vs. the general US population. Furthermore, we tested a focused use case where clinical benefi t should be evident-measuring GI symptoms in patients presenting with disorders aff ecting the GI tract. Despite these multiple eff orts to bolster the potential of GI PROMIS, and our enthusiasm for PROMIS as consortium investigators, we found no diff erence between groups.
Moreover, despite off ering patients access to the e-portal 1 week before their visit, only one-third of patients completed the PROMIS assessments. A likely contributing factor was the "untethered" nature of the e-portal used in this study, as it was not integrated Almario et al.
Michigan GI clinic were eight times more likely to use PROMIS than patients at the other sites. Th e reason behind this is unclear. It is possible that the University of Michigan GI clinic cared for patients that were more "tech-savvy" and willing to use the e-portal. It is also possible that physicians at this clinic were stronger champions of PROMIS, or have a diff erent bond with their patients than those at other clinics; this could not be directly measured. Th ese diff erences indicate that cultural diff erences among clinical settings may infl uence use of PROs such as PROMIS. Although GI PROMIS did not appreciably improve patientcentric outcomes, there are other potential benefi ts to using PROMIS that were not assessed for as part of this study. For instance, we did not measure provider satisfaction; it is possible that clinicians with access to the GI PROMIS reports were more satisfi ed with the clinic encounter. Similarly, we did not evaluate clinic visit effi ciency. Having the PROMIS scores and PROMIS-directed HPI in hand before seeing the patient in the exam room may have allowed clinicians to conduct a more effi cient and meaningful clinic visit, and may also have reduced charting and documenting time. Th ese are areas that are the subjects of future research.
Even though our fi ndings are "negative, " they are still relevant for the fi eld of PRO science. Th e results of this study may inform future research and policy on how best to implement GI PROMIS and other PROs in clinical practice. For example, the passage of the Medicare Access and CHIP Reauthorization Act in 2015 provided the Centers for Medicare and Medicaid an opportunity to update the Medicare EHR Incentive Programs, otherwise known as "Meaningful Use. " One of the aims of the next Meaningful Use iteration is to reward providers for the outcomes that technology helps them achieve with patients ( 32 ) . It remains to be seen how these outcomes will be defi ned as well as the role of PROs, but it will be important for policy makers to recognize that EHR PRO collection alone may be insuffi cient to improve patient outcomes.
In summary, this is the fi rst multicenter controlled trial evaluating the impact of PROMIS on patient outcomes in clinical practice. We found that use of NIH GI PROMIS did not improve patient satisfaction or assessment of provider interpersonal skills and shared decisionmaking. Th ese negative fi ndings may help guide investigators and policy makers in optimizing use of PROs in future clinical practice.
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Guarantor of the article : Brennan M.R. Spiegel, MD, MSHS. Specifi c author contributions : Christopher V. Almario, MD, MSHPM: Planning and conducting the study, collecting and interpreting data, draft ing the manuscript, approval of fi nal draft submitted. William D. Chey, MD: Planning and conducting the study, interpreting data, draft ing the manuscript, approval of fi nal draft submitted. Dinesh Khanna, MD, MSc: Planning and conducting the study, interpreting data, draft ing the manuscript, approval of fi nal draft submitted. Sasan Mosadeghi, MD: Conducting the study, collecting data, draft ing the manuscript, approval of fi nal draft into the EHR. However, we approached non-completers in the clinic itself and off ered help to complete GI PROMIS on a clinic computer while waiting for the doctor, yet most still were uninterested. Notably, our low uptake is similar to fi ndings from Wagner et al. ( 27 ) who tested the feasibility of using PROMIS through a "tethered" e-portal among women receiving gynecologic oncology outpatient care. Th ey found that only 37% of PROMIS assessment requests sent via their EHR portal were completed by patients ( 27 ) . In addition to system-level issues, patient-level factors may have also contributed to the low intervention uptake. While a systematic review found that patients generally have positive attitudes towards e-portals, issues including security concerns, preconceived beliefs about technology, among others, continue to pose important barriers for widespread e-portal adoption ( 28 ) .
In our study, we also noted diff erential uptake of the GI PROMIS intervention by patient characteristics. Namely, we found that African Americans were 56% less likely to complete PROMIS on the e-portal before their visit (adjusted P =0.002). Th ere was also a trend towards lower use of PROMIS among Latinos compared with whites, but this diff erence did not quite reach statistical signifi cance (adjusted P =0.07). Th ese fi ndings are consistent with a number of past reports that also found racial/ethnic disparities in e-portal use (29) (30) (31) . Eff orts to better understand and to address these disparities are critical, as the increasing prevalence of e-portals and other digital health interventions may continue to widen the healthcare gap between whites and minorities.
Th ere were also diff erent rates of GI PROMIS uptake among the four clinical sites. For example, patients at the University of 
WHAT IS NEW HERE
✓ This is the fi rst multicenter controlled trial evaluating the impact of PROMIS on patient outcomes in clinical practice.
✓ One-time use of GI PROMIS did not improve patient satisfaction or assessment of provider interpersonal skills and shared decision-making.
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APPENDIX 
